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Introduction
Colorectal cancer (CRC) is one of the most frequent solid tumours in western countries. In fact, recent estimations indicate that CRC is the third most common cancer both in males and females [1] . The survival rate throughout all stages has improved mainly due to the implementation of screening programs, leading to the detection of CRC in earlier stages, together with the development of more effective treatment options. However, CRC still accounts for about 9% of the estimated cancer-related deaths [1] .
Resistance of cancer cells to apoptosis is one of the so-called hallmarks of cancer [2] . Since impairments in the intrinsic apoptotic pathway are often involved in this resistance, targeting the extrinsic apoptotic pathway is especially attractive for cancer therapy [3, 4] . Among the death ligands capable of triggering apoptosis through the extrinsic pathway, CD95L showed a remarkable strong cytotoxic potential on cancer cells. However, disappointingly it also displayed a severe systemic toxicity, therefore making unrealistic its use as anti-cancer agent [5] . On the other hand, another death ligand, namely tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), was found to be able to induce apoptosis in tumour cells without affecting most normal cells [6, 7] . Hence, it was soon considered as potentially useful for anticancer therapy [8, 9] . However, despite the encouraging initial results, TRAIL-based therapies showed very limited therapeutic activity in phase II/III clinical trials carried out on a wide variety of human cancers [3, 10] . In order to overcome TRAIL resistance, better sensitization strategies [11] [12] [13] , as well as novel TRAIL formulations with improved bioactivity can be of great usefulness for its future clinical use [14] [15] [16] [17] .
TRAIL has four membrane-bound receptors in humans: TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2 [18] [19] [20] [21] [22] [23] [24] . In addition, TRAIL M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 has been described to be able to bind to the soluble receptor osteoprotegerin (OPG) [25] . Among these five receptors, only DR4 and DR5 are able to transduce the apoptotic signal upon TRAIL binding. Although they share high similarity, both receptors present certain functional differences. For example, DR5 has been described to present higher affinity for TRAIL [26] . However, apparently DR5 requires further clustering, so it can only be properly activated by membrane-bound TRAIL or by artificially cross-linked versions of the molecule [27, 28] . On the contrary, DR4 can readily be activated by soluble versions of TRAIL, although cross-linked versions of TRAIL proved again to be more active than soluble TRAIL [29] . Regarding the relative contribution of both receptors to TRAIL-induced apoptosis, DR4 has been described to be the pre-eminent pro-apoptotic receptor in haematological cells, while in epithelial cells expressing both receptors DR5 appears to be the main pro-apoptotic receptor [30] [31] [32] [33] [34] . However, the differential contribution of both receptors is still controversial.
Our group demonstrated that, in physiological conditions, TRAIL was indeed released by activated human T cells in its transmembrane form, inserted in the membrane of lipid microvesicles called exosomes [35, 36] . On this basis, we have generated artificial lipid nanoparticles containing membrane-bound TRAIL (LUV-TRAIL) resembling those natural exosomes. We already demonstrated that LUV-TRAIL was more effective inducing apoptosis than soluble TRAIL against leukemia cells that presented resistance to soluble TRAIL and chemotherapeutic drugs [37, 38] and also in epithelial-derived cancer cells [39, 40] . This increased cytotoxicity induced by LUV-TRAIL was due to a superior DR5 activation, which led to an enhanced DISC recruitment [40, 41] .
In the present work, we have tested LUV-TRAIL in several human colon tumour 
Materials and Methods
Generation of liposomes covered with soluble recombinant TRAIL.
Large Unilamellar Vesicles (LUV) with soluble recombinant TRAIL (hereafter sTRAIL) anchored on their surface were generated as previously described [37, 42] .
Briefly, after generating the lipid nanoparticles, a version of sTRAIL (rTRAIL-His 6 , corresponding to amino acids 95-281, kindly provided by Dr. M. MacFarlane [22] ) was attached to their surface by incubation at 37ºC for 30 minutes.
Cell culture.
HCT-116, HT29 and CACO-2 cell lines were obtained from ATCC. 
Nuclear morphology analysis.
Cytotoxicity assays were performed seeding cells (1x10 5 cells) onto cover slips placed in 6-well plates with complete medium, and treated with sTRAIL and LUV-TRAIL at 500 ng/mL for 6 hours. After that, nuclear morphology was analysed by fluorescence microscopy by staining with Hoechst 33342 (Life Technologies) as previously described [39] .
Western blot analysis.
For protein expression analysis, Western blot was performed as previously described [38] . The following antibodies were used to analyse the expression of the main proteins involved in the extrinsic apoptotic pathway: anti-caspase-8 (BD Biosciences), anti-caspase-3 (Cell Signaling), anti-Bid (BD Biosciences), anti-PARP-1 (BD Biosciences), anti-Bax (BD Biosciences), and anti-Bak (BD Biosciences). As loading control, expression of ȕ-actin was analysed using a specific antibody (Sigma).
For higher-order TRAIL oligomers analysis, sTRAIL or LUV-TRAIL were incubated with the indicated amounts of the cross-linker BS3 (Thermo) for 30 minutes at room temperature. Then, Tris/HCl was added at a final concentration of 50 mM to quench the reaction, and after thorough mixing, the mix was settled for 15 minutes at room temperature. Finally, sample buffer containing 1% SDS was added to each sample. After heating for 5 minutes at 96ºC, samples were separated by SDS-PAGE in gels containing 6% acrylamide/bisacrylamide, and analysed by Western blot. 
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Finally, death-receptor expression and sensitivity to sTRAIL and LUV-TRAIL was analysed both on tumour-derived and parental cells as above described.
Statistical analysis.
Data were analysed using Prism® software program (GraphPad Software, San Diego, CA On the other hand, the long-term effect of LUV-TRAIL on the survival and proliferation of CRC cell lines was assessed by performing clonogenic assays ( Fig.1.B) .
In all cases, treatment with LUV-TRAIL for 24 hours significantly reduced clonogenic
survival of CRC cells more efficiently than sTRAIL. These data would indicate that LUV-TRAIL not only has a stronger short term effect than sTRAIL but also that it has a long-term effect affecting to survival and proliferation of CRC cells.
To assess if the observed decrease of cell viability implied an apoptotic process, several features of apoptosis were analysed. First of all, nuclear morphology after TRAIL treatment was studied ( Fig.2 .A). HCT-116 cells showed typical morphological features of apoptotic cell death such as blebbing and cell shrinkage (yellow arrows).
Remarkably, apoptotic nuclear changes were more numerous and apparent when cells were treated with LUV-TRAIL, and importantly these nuclear changes correlated with cell death analysed in parallel using PI staining. On the other hand, phosphatidyl-serine translocation was studied by annexin-V staining upon treatment with both forms of TRAIL (sTRAIL and LUV-TRAIL, Fig.2 
.B). In HCT-116, HT29 and CACO-2 cells,
LUV-TRAIL exhibited a greater ability to induce apoptosis than sTRAIL. Altogether, these results perfectly correlated with the cell viability assays showed in Fig.1 .A in all cases except for HCT-116 BB cells, where no apoptosis was observed neither with sTRAIL nor with LUV-TRAIL.
To assess that LUV-TRAIL-induced apoptosis was due to a TRAIL-specific effect, pre-incubation with the TRAIL-blocking antibody RIK2 was performed before treatment with both TRAIL formulations. In all cases, apoptosis induced by either sTRAIL or LUV-TRAIL was entirely abrogated (Fig.2 .B) corroborating that apoptosis induced by LUV-TRAIL exclusively relied on the presence of TRAIL on the liposome surface. In this line, it is important to point out that LUVs alone (without TRAIL on their surface) did not show any pro-apoptotic effect in any CRC cell line (see controls in Fig.2 ) Therefore, it could be concluded that the cytotoxic effect of LUV-TRAIL was M A N U S C R I P T
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13 exclusively due to the action of TRAIL, discarding any non-specific effect that could be attributed to the liposomal particles.
3.2. LUV-TRAIL are able to induce a stronger activation of the extrinsic apoptotic pathway than sTRAIL in CRC cell lines.
To further characterize that cell death induced by LUV-TRAIL was an apoptotic process, inhibition assays were carried out using the pan-caspase inhibitor z-VAD-fmk (Fig.S3 ). z-VAD-fmk was able to fully inhibit cell death both in HCT-116 and HT29 cells when treated with forms of TRAIL indicating that LUV-TRAIL-induced cell death is a caspase-dependent process.
Next, activation of the extrinsic apoptotic pathway was assessed by Western blot Fig.2 . However, surprisingly PARP1 cleavage was quite clear, starting after only 1 hour of treatment with LUV-TRAIL. To better characterize this apparent discrepancy, caspase-3 activation was quantified by using a colorimetric assay. As shown in Fig. S4 .E, the activation pattern of caspase-3 in wild-type HCT-116 was in agreement with the Western blot in Fig. 3 . For HCT-116 BB, caspase-3 activity was clearly diminished in comparison to the wild-type cells. However, a marginal activity could be detected, which could account for the PARP1 cleavage observed, but would not be able to fully undergo apoptosis. Altogether, this is the typical pattern expected from a type-II cell line, in which the activation of the mitochondrial apoptotic branch is mandatory for the execution of the apoptotic program. Finally, the highly resistant cell line CACO-2 showed certain activation of caspase-8 upon LUV-TRAIL treatment, but to a much lesser extent than the other cell lines, (Fig.S4.B) . Accordingly, some activation of caspase-3 and cleavage of PARP-1 could be detected, which correlated with the observed slight induction of apoptosis (Fig.S4.D) .
LUV-TRAIL enhanced pro-apoptotic potential relies on the formation
of supra-molecular TRAIL oligomers.
Up to this point it was clear that LUV-TRAIL exhibited a higher pro-apoptotic potential than the soluble version of TRAIL. Our hypothesis was that the membranebound TRAIL present in the LUV-TRAIL formulation would form supra-molecular TRAIL oligomers that, in turn, would activate the main pro-apoptotic TRAIL receptor DR5 more efficiently than sTRAIL. To confirm that assumption, we carried out a crosslinking analysis in order to see the formation of supra-molecular TRAIL oligomers on the liposomal surface. The artificial cross-linker BS3 was added to sTRAIL or LUV-M A N U S C R I P T
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TRAIL at increasing concentrations to stabilize the different TRAIL-oligomer populations, and samples were resolved by SDS-PAGE and Western Blot analysis (Fig.4.A) . BS3 cross-linking of LUV-TRAIL allowed the detection of supra-trimeric populations of high molecular order. However, these higher-order oligomers could not be detected in sTRAIL. In order to study in more detail these high-order oligomers seen in LUV-TRAIL, the cross-linker BS3 was added to sTRAIL or LUV-TRAIL to stabilize the different TRAIL populations, and samples were analysed by HPLC (Fig.4.B and C) . Fig.4.B) .
On the other hand, the actual ability of sTRAIL and LUV-TRAIL to cluster TRAIL receptors on the cell surface was assessed on HCT-116 cells by allowing the cells to be stimulated with either sTRAIL or LUV-TRAIL for up to one hour, and then performing non-reducing SDS-PAGE followed by immunoblotting. As shown in the main pro-apoptotic receptor in these cells. However, importantly, significant differences between sTRAIL and LUV-TRAIL could still be detected at the highest concentrations (300 and 1000 ng/ml).
On the other hand, knockdown of DR5 did not have an important effect on the overall sensitivity of the cells neither to sTRAIL nor LUV-TRAIL, but the differences between sTRAIL and LUV-TRAIL disappeared (Fig.5.B, right panel) . These data strongly suggested that the main difference between sTRAIL and LUV-TRAIL is their relative ability to activate DR5. Altogether, these results clearly indicated that the presence of higher order TRAIL oligomers on the liposomal surface was directly linked to the clustering of DR5 on the cell surface, ultimately leading to a higher cytotoxic effect.
LUV-TRAIL shows a significantly higher in vivo antitumor activity than soluble TRAIL in a human tumour CRC xenograft model.
Before performing in vivo experiments, cytotoxicity assays in 3-D cell cultures were carried out. For this purpose, we used a novel technology based on microfluidic devices which resembles more accurately the in vivo conditions in which cancer cells grow [44] [45] [46] . Confirming the in vitro results, LUV-TRAIL showed a higher cytotoxic effect than sTRAIL against HCT-116 cells also in 3-D cell cultures (Fig.6.A and B) . showed a better antitumor effect than sTRAIL against HCT-116-derived tumours. The difference between both forms of TRAIL was clear, being significant already at day 13 ( Fig.6.C) . Surprisingly, sTRAIL did not reduce nor delay tumour growth respecting to the Control group (Fig.6.D) . This would be most likely due to the poor stability and M A N U S C R I P T
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pharmacokinetic profile of sTRAIL [47, 48] , which would inactivate the molecule by the time it reached the tumour site.
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Discussion
Despite the initial optimism that TRAIL incited as a possible new and highly selective antitumor agent, the clinical effectiveness of TRAIL, both in monotherapy and in combined regimes, has been disappointing [3, 4, 10] . It is currently accepted that in order to overcome the poor responsiveness of some cancers to recombinant TRAIL formulations currently available [17] it appears as absolutely indispensable to improve its pro-apoptotic potential by the development of novel TRAIL formulations [15] .
In this line, our group previously demonstrated that human lymphocytes secrete TRAIL preferably associated with lipid vesicles called exosomes [35, 36] Aiming to mimic this exosome-bound TRAIL, we generated the novel TRAIL formulation LUV-TRAIL, based on anchoring this death ligand on Large Unilamellar Vesicles (LUV) resembling these natural exosomes. LUV-TRAIL has been proved to be much more potent than soluble TRAIL both in haematological malignancies [37, 38, 41] and solid tumours [39, 40] . Remarkably, the soluble version of TRAIL used in all those studies is virtually identical to the version used in clinical trials (Dulanermin®), which confers more significance to LUV-TRAIL improved efficiency.
Pursuing to further analyse the effectiveness of LUV-TRAIL in solid tumours, we laid our focus on CRC cancer. We tested our liposomal formulation on a panel of four different CRC cell lines presenting a heterogeneous sensitivity to sTRAIL induced apoptosis. Although in some particular cases LUV-TRAIL showed similar proapoptotic ability than sTRAIL, in general LUV-TRAIL was shown to be more active Among the two TRAIL pro-apoptotic receptors, DR5 has been described as the main DR responsible for TRAIL-induced apoptosis in some epithelial-derived cancer cells such as breast and ovarian carcinoma [32, 34] . Regarding CCR cells, both DRs have been implicated in TRAIL-induced apoptosis [52, 53] . On the other hand, TRAIL exhibits a much stronger cytotoxicity when it is artificially cross-linked, and this increased bioactivity directly relies on its ability to cluster its pro-apoptotic receptors in supra-molecular structures larger than merely trimers [27, 54] . Indeed, it has been previously demonstrated that the enhanced clustering of TRAIL receptors is related with an improved DISC recruitment [49] [50] [51] . In this line, it has been described that DR5
requires further cross-linking for a correct activation [27, 28] . In fact, co-treatment of soluble TRAIL with an agonistic anti-DR5 antibody allowed an enhanced DR5 activation mediated by the artificial cross-linking of this receptor facilitated by the agonistic antibody [55, 56] . We previously demonstrated that the enhanced cytotoxicity showed by LUV-TRAIL in human leukemic cells relied on their higher efficiency for promoting DR5 clustering leading to a higher DISC recruitment [41] . In the present study, we wanted to corroborate this feature also in CRC cells. In this regard, the relative apoptotic contribution of DR4 or DR5 in HCT-116 has been indeed addressed in the literature by using different approaches. Those reports showed somehow contradictory results: whilst in some of them DR4 appears to be the pre-eminent pro-apoptotic receptor, in others it is DR5 [52, 53, [57] [58] [59] . These differences might as well be explained by the use of different agonistic molecules in those studies.
Some of those studies were conducted using different monoclonal agonistic antibodies against DR4 or DR5, however, the use of monoclonal antibodies as TRAIL-receptor agonists is a delicate matter. Although originally seen as a more specific and reliable way to activate DR4 or DR5, it was later shown that in certain cases those antibodies
were not able to induce apoptosis on their own and required further crosslinking. An additional layer of complexity in this regard relies on the actual localization of the M A N U S C R I P T
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22 receptors within specific membrane micro-domains on the cell surface, which could be directly involved in the requirement for further oligomerization of DR5 between different cell lines [60] [61] [62] [63] . In any case, it appears that using improved TRAIL-derived formulations instead of antibodies might be advantageous given that TRAIL bear the potential to simultaneously activate both DR4 and DR5.
Although LUV-TRAIL has been proved to be more active than sTRAIL in all experimental settings tested so far, there are still some caveats regarding its possible use as a therapeutic agent. Before testing the in vivo antitumor potential of LUV-TRAIL, we first tested its performance in a more complex scenario based on culturing the cells in a three-dimensional matrix embedded in a central chamber in small polymer chips [64, 65] . In this model, sTRAIL or LUV-TRAIL were perfused through lateral channels, and the agents should be able to diffuse into the matrix and reach the cells inside the chamber, somehow similarly to physiological extravasation processes. In accordance with its much bigger size, previous results showed that LUV-TRAIL exhibited a much slower diffusion rate through the matrix than sTRAIL (data not shown), which could actually represent a serious handicap regarding its pro-apoptotic efficiency. However, despite its low diffusion rate, LUV-TRAIL not only retained its cytotoxicity, but it showed again a much higher pro-apoptotic ability than sTRAIL.
Finally, we tested the in vivo potential of sTRAIL and LUV-TRAIL using and retention (EPR) effect. According to the EPR effect, thanks to their size, nanoparticles in the range of 100 nm of diameter tend to spontaneously localize in tumour sites by extravasation through the leaky defective blood capillary irrigating the tumour. This EPR effect has been described to be an inherent property of nanoparticles independently of the composition of the particles [66] .
Although the use of liposomes for the treatment of diseases of different kind has been extensively described, liposome platforms have been always used as vehicle to encapsulate drugs inside their lumen, improving their stability and pharmacodynamic
properties [67] [68] [69] . However, the original idea of using of liposomes as a platform to attach TRAIL on their surface, increasing its bioactivity, was firstly developed and described by our group. The present study validates this TRAIL formulation not only as a potential tool for the treatment of haematological malignancies as previously reported, but also as a novel antitumor therapeutic strategy for colorectal cancer. show the mean ± SD of at least three independent experiments. *p<0.05, ***p<0.001. 
